WE'RE DEDICATED TO FINDING ATREATMENT FOR SMA
In collaboration with Astellas, Cytokinetics is developing reldesemtiv (CK-2127107), a next-generation fast skeletal muscle troponin activator (FSTA) as a potential treatment for people living with debilitating diseases and conditions associated with neuromuscular or non-neuromuscular dysfunction, muscular weakness, and/or muscle fatigue.
Reldesemtiv is an investigational drug candidate intended to slow the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers. Reldesemtiv is a next-generation skeletal muscle compound that may improve muscle function and physical performance in people with SMA, COPD, elderly adults with limited mobility and ALS.
Reldesemtiv has been the subject of five completed Phase 1 clinical trials in healthy volunteers, which evaluated safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics.
Reldesemtiv was the subject of a Phase 2, hypothesis-generating clinical study in patients with Type II, Type III and Type IV SMA. The study showed dose- and concentration-dependent increases in time to muscle fatigue as measured by changes from baseline in Six Minute Walk Distance (6MWD), a sub-maximal exercise test of aerobic capacity and endurance, and Maximal Expiratory Pressure (MEP), a measure of strength of respiratory muscles, after eight weeks of treatment with reldesemtiv.
Reldesemtiv is also currently the subject of three ongoing clinical trials: a Phase 2 trial evaluating its effect on physical function and exercise tolerance in patients with COPD, a Phase 2 trial investigating its effect on measures of respiratory function and skeletal muscle function in patients with ALS, and a Phase 1b trial investigating its effect on measures of physical function in elderly adults with limited mobility.